




LEARN MORE -
START A PARTNERSHIP +1 (877) 727-6275

YOUR BIOAVAILABILITY BREAKTHROUGH: INTRODUCING MICRODEP



IS INCONSISTENT ABSORPTION CAPPING YOUR ROI?

For too long, traditional oral delivery has restricted APIs: fluctuating plasma levels, wasted product, food effects, sub-optimal patient experience. At ARx, we understand these challenges intimately. That's why, for over 60 years, we have pioneered advanced technologies, such as those for oral and transmucosal delivery—developing the first FDA approved oral thin films for systemic drug delivery to consistently redefine what's possible.

Today, we proudly introduce MicroDEP, a patented micro deposition technology designed for potent, low-dose APIs.

THE MICRODEP FORMULATION ADVANTAGE

- ✓ Up to 82% API bioavailability with consistent, controlled dosing.
- ✓ Therapeutic effects within minutes due to swift mucosal absorption.
- ✓ Precision deposition minimizes waste and maximizes potency.
- ✓ Discreet, non-invasive delivery improves adherence and comfort.
- ✓ Enabling the delivery of potent API's

FROM INCONSISTENT ABSORPTION TO PREDICTABLE PRECISION

1. **Precise API Deposition:** Controlled API droplets are precisely deposited onto a dissolvable thin film.
2. **Optimized Film Dissolution:** The polymer film disintegrates upon mucosal contact for complete API release. MicroDEP dosage forms are designed to be dissolvable over a specific time, or designed to be non-dissolvable and easily removed.
3. **Direct Mucosal Delivery:** Sublingual/buccal route of administration bypasses the first-pass metabolism for reliable, systemic uptake.
4. **Integrated Quality & Scale:** ARx's end-to-end expertise guarantees consistent, scalable production in full compliance to cGMP quality standards.





LEARN MORE -
START A PARTNERSHIP +1 (877) 727-6275

YOUR END-TO-END PATHWAY TO COMMERCIAL SUCCESS



MicroDEP Formulation Development:

Maximize API mucosal delivery with tailored thin film formulations.



CMC Product Development:

End-to-end CMC support for rapid filing and commercialization.



Analytical Testing:

In-house method development and rigorous QC.



Process Development & Optimization:

QbD-driven scaling for efficient, consistent thin film technology production.



Quality & Regulatory Support:

Expertise in FDA and cGMP compliance for IND/ANDA/NDA submissions.




Commercial Manufacturing:

Over 100M+ units produced annually in FDA-registered, cGMP facilities.




LOOKING TO INTEGRATE YOUR API INTO A NEXT-GEN DELIVERY SYSTEM?

Partner with ARx to transform your therapeutic concepts into scalable, regulatory-compliant products.

 **Phone:** +1 (877) 727-6275
Toll-Free: +1 (877) 727-6275

 marketing@arxpharma.com

 400 Seaks Run Rd.
Glen Rock, PA 17327

OFFER THE LATEST IN DRUG DELIVERY TECHNOLOGY

82%

The highest bioavailability of any FDA-approved thin film.

5


Quantifiable therapeutic effect within 5 minutes.

1st

The first FDA-approved microdeposited thin film.

9

Proven quality system with 9 positive FDA inspections.



For More Information, Please Visit:
arxpharma.com